相似文献
1
Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group.
Bone Marrow Transplant. 2024 Jun;59(6):896-898. doi: 10.1038/s41409-024-02260-z. Epub 2024 Mar 9.
2
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol. 2021 Nov;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13.
3
Transfusion management in multiple myeloma patients receiving daratumumab: Experience of a single tertiary care centre.
Transfus Apher Sci. 2020 Apr;59(2):102658. doi: 10.1016/j.transci.2019.09.011. Epub 2019 Oct 4.
4
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Ann Hematol. 2021 Apr;100(4):1059-1063. doi: 10.1007/s00277-020-04374-y. Epub 2021 Feb 2.
5
Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report.
Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):e21-e24. doi: 10.1016/j.clml.2020.08.019. Epub 2020 Sep 17.
6
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
J Manag Care Spec Pharm. 2021 Dec;27(12):1691-1702. doi: 10.18553/jmcp.2021.27.12.1691.
7
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Lancet Haematol. 2020 Dec;7(12):e874-e883. doi: 10.1016/S2352-3026(20)30356-2.
8
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol. 2021 Oct;22(10):1378-1390. doi: 10.1016/S1470-2045(21)00428-9. Epub 2021 Sep 13.
9
[Daratumumab for multiple myeloma].
Bull Cancer. 2018 Nov;105(11):985-991. doi: 10.1016/j.bulcan.2018.09.003. Epub 2018 Oct 24.
10
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.
引用本文的文献
1
Impact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study.
Ann Hematol. 2025 Sep 5. doi: 10.1007/s00277-025-06581-x.
2
From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis.
Blood Adv. 2025 Aug 26;9(16):4311-4316. doi: 10.1182/bloodadvances.2025016586.
3
Impact of induction regimens on stem cell mobilization yields in newly diagnosed multiple myeloma.
Ann Hematol. 2025 Apr;104(4):2297-2304. doi: 10.1007/s00277-025-06372-4. Epub 2025 Apr 25.
4
Effects of Daratumumab on Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Are Planned to Receive Autologous Transplantation: What's the Relevance?
Mediterr J Hematol Infect Dis. 2024 Sep 1;16(1):e2024073. doi: 10.4084/MJHID.2024.073. eCollection 2024.
本文引用的文献
1
The Impact of CD34 Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma.
Clin Lymphoma Myeloma Leuk. 2023 Nov;23(11):850-856. doi: 10.1016/j.clml.2023.07.014. Epub 2023 Aug 14.
2
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med. 2022 Jul 14;387(2):132-147. doi: 10.1056/NEJMoa2204925. Epub 2022 Jun 5.
3
How I treat triple-class refractory multiple myeloma.
Br J Haematol. 2022 Jul;198(2):244-256. doi: 10.1111/bjh.18185. Epub 2022 Apr 3.
4
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.
Haematologica. 2021 Aug 1;106(8):2257-2260. doi: 10.3324/haematol.2020.261842.
5
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2021 Mar;32(3):309-322. doi: 10.1016/j.annonc.2020.11.014. Epub 2021 Feb 3.
6
CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity.
Front Immunol. 2020 Nov 30;11:597959. doi: 10.3389/fimmu.2020.597959. eCollection 2020.
7
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
8
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288.
9
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
10
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.
Zotero 插件